Hepatocyte Transplantation for Acute Decompensated Liver Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine whether liver cell transplantation can provide help for patients with liver failure who are unlikely to survive without some form of liver support. The goal of this research study is to determine if liver cell transplants can be effective until a liver transplant is received or until patients recover from their liver failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Fetal Liver Cell Transplantation in Chronic Liver Failure

NCT01013194

Liver Cirrhosis

COMPLETED PHASE1/PHASE2

Micro-encapsulated Hepatocyte Intraperitoneal Transplantation in Liver Failure Adults

NCT05727722

Acute-On-Chronic Liver Failure Chronic Liver Failure

RECRUITING PHASE1

Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis

NCT00393185

Primary Biliary Cirrhosis

WITHDRAWN PHASE1

Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure

NCT00225901

Liver Failure, Acute

UNKNOWN PHASE1/PHASE2

G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease

NCT01384565

Chronic Liver Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Orthotopic liver transplantation has become the treatment of choice for patients with acute liver failure with poor prognostic signs. Survival following hepatic transplantation has improved in the last decade for a number of reasons. These include improvement in immunosuppression, improved methods for preserving and transporting organs, use of donors which had been previously considered unacceptable, use of reduced-sized grafts , and the use of living-donor hepatic transplantation. Despite encouraging survival statistics, there continues to be significant morbidity and mortality associated with hepatic transplantation. In addition, the success of hepatic transplantation has broadened the indications for this form of therapy without a concomitant increase in the number of donors available for these patients.

Since the development of a method for isolating primary hepatocytes by collagenase perfusion, many investigators have demonstrated the efficacy of hepatocyte transplantation in the treatment of liver failure and inherited metabolic disorders in experimental animals. Treatment of liver diseases with transplantation of isolated hepatocytes rather than the whole liver has several theoretical advantages. Unlike the whole liver, isolated hepatocytes could be cryopreserved for instant availability and could be modified genetically or otherwise to enhance specific functions, stimulate proliferation or abrogate allograft rejection. Hepatocyte transplantation should be less stressful than whole liver transplantation because the host organ remains intact. Since the transplanted cells integrate into the host liver, they could provide restorative potential and the consequences of graft loss would be relatively minor. In addition, hepatocyte transplantation would not interfere with subsequent liver transplantation, should that become necessary.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Failure Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hepatocyte Transplantation

See Below

Group Type EXPERIMENTAL

human hepatocytes

Intervention Type DRUG

The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.

We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

human hepatocytes

The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.

We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects will include those patients with ALF who are potential conventional liver transplant recipient candidates based on PELD criteria as well as those who would not be considered candidates for orthotopic liver transplantation (e.g. patients who appear to be too small or too ill for solid organ transplant or those who have a diagnosis that is a contradiction for whole organ transplantation, for example, systemic mitochondrial hepatopathy).
* If the patient is a candidate for orthotopic liver transplantation (per standard clinical criteria), they will be officially listed for liver transplantation as well as hepatocyte transplantation.
* If a subject is a potential conventional liver transplant recipient candidate and a donor liver is available; the patient will receive a solid organ transplant.
* Subjects ages 0-21 years old will be included in this study.

Exclusion Criteria

The patient has:

1. Severe cardiovascular or respiratory disease at baseline and at the time of hepatocyte transplant as defined by

1. Central venous pressure \>25 mm Hg or if known, pulmonary capillary wedge pressure of \>30 mg Hg or
2. Oxygen saturation of \<90% on \> 60% oxygen OR a P/F ratio (Po2/FiO2) of \<1.
2. Hemodynamically significant gastrointestinal bleeding causing a systolic blood pressure \<70mmHg at the time of transplantation.
3. Uncorrectable coagulopathy despite use of plasmapheresis that would preclude any invasive procedures.
4. Leukopenia at the time of cell transplant, defined as an absolute neutrophil count of \<500/µL.
5. Known allergy to immunosuppression medications that are required post transplant procedure for the prevention of rejection.
6. Active malignancy except those with acute liver failure during treatment with estimated life expectancies of \>1 year if the malignancy is controlled.
7. Sepsis or other active infection except those without evidence of hemodynamically significant uncontrollable systemic sepsis with positive blood or tissue cultures.
8. Intrauterine pregnancy. All females of childbearing potential will receive a pregnancy test prior to enrollment.

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No